Pfizer's Dividend Yield Is Enormous. But Is the Payout Still Growing?

Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.

24/7 Wall Street • 17 hours ago

2 High-Yield Dividend Stocks to Buy and 1 to Avoid

Pfizer's free cash flow is not covering its dividend, and the company faces a patent cliff. Energy Transfer is one of the biggest beneficiaries of strong natural demand coming from the AI data center build-out.

The Motley Fool • 12 hours ago

3 Dividend Stocks to Buy and Hold for 10 Years

Pfizer has a deep pipeline that could help improve its approved lineup and financial results over the medium term. Abbott Laboratories' core medical device business remains strong, and the company has attractive opportunities elsewhere.

The Motley Fool • 10 hours ago

Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.

Pfizer's management remains firmly committed to maintaining the dividend. The company's growth portfolio is performing well.

The Motley Fool • Sep 17, 2026

How a Roth IRA Can Keep Thousands More of Your High-Yield Dividend Income Compounding

Where you hold a high-yield dividend stock matters almost as much as which one you pick, and for ordinary-income payers like BDCs and REITs, the wrong account quietly erodes a portion of every distribution before it ever compounds.

24/7 Wall Street • Sep 16, 2026

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Sep 15, 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Executive Vice President, at the J.P. Morgan U.S. All Stars 2026 Conference on Tuesday, September 22, 2026 at 11:50 a.m. BST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors.

Business Wire • Sep 15, 2026

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

Zacks Investment Research • Sep 15, 2026

Pfizer's 6% Yield Masks a Fragile Dividend Story

Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves almost no room for error.

24/7 Wall Street • Sep 14, 2026

Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage

Pfizer NYSE: PFE Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining COVID-19-related demand and upcoming losses of exclusivity for certain products.

MarketBeat • Sep 14, 2026